NeuroPerspective is the quarterly journal that pioneered the coverage of cutting-edge therapies being developed for disorders of the central nervous system, including Alzheimer’s, Parkinson’s, stroke, brain injury, schizophrenia, and depression–and the companies pursuing them. It enjoys worldwide readership and recognition for its ‘no-holds-barred’ evaluations. Three issues each year cover three therapeutic areas in depth, along with concise company overviews, coverage of corporate events (licensings, funding, M&A) in the CNS area, and reports on scientific advances.  The Winter (January) issue reviews the developments and trends that emerged during the previous year, and previews what to expect in the year to come.

NP’s role is twofold: First, it is a ‘one-stop’ resource for the information that everyone in the neurotherapeutics world needs in order to stay abreast of this highly complex field, both in terms of the science and the business components that comprise the sector. But NP is not a passive reporter of events and advances: In a world where unmet medical needs remain outsized, and resources are constrained, we abhor programs that waste precious fiscal and scientific resources; the companies who go through the motions of pursuing progress; and those who substitute PR glitz for the hard work of discovery and development. We give companies a fair hearing regarding their strategic choices and tactical execution, but we do not shy away from calling them out when they fall short on either count.

1 year subscription: $3200 for 1-5 user license: Startup, academic rates available: Contact us at